# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Instead, a Senior Vice President in charge of coordination and management of synergistic projects between China and US and mana...
CASI Pharmaceuticals (NASDAQ:CASI) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of ...
CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a Cayman incorporated biopharmaceutical company focused on developing and commerciali...
CASI: 92% | CASI Pharmaceuticals Announced Plan To Submit CID-103 IND Application; Also Announces Receipt Of A Non-binding Prop...
HC Wainwright & Co. analyst Sean Lee maintains CASI Pharmaceuticals (NASDAQ:CASI) with a Buy and lowers the price target...